
Longduoduo Co Ltd
93
Recent news coverage includes broader market and regulatory developments relevant to Chinese companies and the healthcare sector but does not specifically mention Longduoduo.
- President Donald Trump claims to have significant veto power that could impact the AI trade and related market dynamics [N1].
- Jensen Huang's departure as Nvidia CEO is noted for potential consequences in the crypto market, reflecting broader tech sector shifts [N2].
- Incyte received European approval for Povofortay in treating Hidradenitis Suppurativa, indicating regulatory progress in healthcare [N3].
- Tencent Music Entertainment Group reported increased Q3 sales, reflecting positive trends in Chinese tech-related sectors [N4].
- Discussions on social security claiming strategies highlight financial planning considerations for investors [N5].
- Beneficient reported its second quarter fiscal 2027 results, contributing to sector earnings updates [N6].
- Delek US Holdings repaid and terminated a term loan credit agreement, indicating corporate finance activity [N7].
- EPR Properties closed a $575 million convertible senior notes offering, reflecting capital market activity [N8].
Longduoduo Co Ltd functions exclusively as a holding company incorporated in Nevada, with all business operations conducted through seven subsidiaries located in the People's Republic of China. These subsidiaries operate in the healthcare sector, focusing on preventive healthcare solutions including disease screening and treatments primarily targeting cardiovascular and cerebrovascular diseases and gastrointestinal disorders. The company’s revenue is predominantly derived from commissions earned through agency relationships with a third-party healthcare service provider, Inner Mongolia Honghai Health Management Co., Ltd. The corporate structure includes intermediary holding companies in Hong Kong and the British Virgin Islands. The company faces regulatory and operational risks stemming from PRC laws, foreign exchange controls, and restrictions on upstream profit distributions. Financially, the company has reported ongoing losses and liquidity ratios slightly above 1.0 as of the latest quarter ending September 30, 2026.
Longduoduo Co Ltd is a Nevada holding company operating through seven subsidiaries in China, primarily engaged in health consulting and preventive healthcare services. The company generates most of its revenue from commissions on health maintenance services provided by a third-party healthcare provider under agency agreements. Financial disclosures as of September 30, 2026, show limited revenue, ongoing net losses, and liquidity ratios slightly above 1.0. The company faces significant regulatory risks related to its Chinese operations, including restrictions on profit distributions, foreign exchange controls, and compliance with evolving PRC laws. Management has expressed substantial doubt about the company's ability to continue as a going concern. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Longduoduo's business model leverages agency relationships to provide preventive healthcare services in China, a market with growing demand for health maintenance and disease prevention. The company's corporate structure allows it to operate within the regulatory framework of China while accessing capital markets in the U.S. The presence of multiple subsidiaries focused on health consulting and preventive care could enable diversification of service offerings. The company’s auditor is subject to PCAOB inspections, which supports transparency and investor confidence. If regulatory conditions remain stable, the company may maintain its operational continuity and pursue growth through its agency agreements.
Longduoduo faces significant risks from its dependence on a single third-party healthcare provider for nearly all its revenue, which may limit revenue diversification and growth. The company has incurred ongoing losses and negative cash flows, with management expressing substantial doubt about its ability to continue as a going concern. Regulatory risks in China, including restrictions on profit distributions, foreign exchange controls, and evolving cybersecurity and anti-monopoly laws, could materially impact operations and financial condition. The company's status as a Nevada holding company with operations in China exposes it to geopolitical and legal uncertainties, including potential delisting risks under the HFCAA. These factors collectively pose challenges to the company's financial stability and operational sustainability.
Longduoduo's moat is limited due to its reliance on agency agreements with a single third-party healthcare provider for the majority of its revenue. The company's structure as a holding company with operations conducted through subsidiaries in China exposes it to regulatory and operational risks that may constrain competitive advantages. The healthcare services sector in China is competitive and subject to evolving regulatory oversight, which may limit Longduoduo's ability to differentiate or secure long-term exclusive arrangements. The company's dependence on upstream profit distributions from its Chinese subsidiaries further constrains its financial flexibility.
• Regulatory Risks in China: Longduoduo's operations are subject to extensive PRC regulations including restrictions on profit distributions, foreign exchange controls, cybersecurity, anti-monopoly enforcement, and listing approvals by the China Securities Regulatory Commission. Changes or enforcement of these regulations could materially affect the company's operations and financial condition.
• Concentration Risk: Over 99.6% of Longduoduo's revenue is derived from commissions earned through agency agreements with a single third-party healthcare provider, creating significant dependency and risk if this relationship changes or terminates.
• Going Concern and Financial Stability: The company has incurred ongoing operating losses and negative cash flows, with management expressing substantial doubt about its ability to continue as a going concern. Failure to secure additional financing or improve revenue could materially harm the business.
• Geopolitical and Legal Risks: As a Nevada holding company with all operations in China, Longduoduo faces risks related to U.S.-China relations, enforcement of U.S. securities laws, and potential delisting risks under the Holding Foreign Companies Accountable Act if audit inspections are restricted.
Business trends: Continued reliance on agency commissions from a single healthcare provider within a complex regulatory environment in China.
Execution milestones: Navigating PRC regulatory approvals, managing liquidity and operational continuity amid ongoing losses.
Key risks: Regulatory restrictions on profit distributions, geopolitical tensions, concentration risk, and going concern uncertainties.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Longduoduo Co Ltd is a Nevada holding company incorporated on October 25, 2021, with principal operations conducted through seven subsidiaries located in the People's Republic of China (PRC).
- The company owns its Chinese subsidiaries through intermediary holding companies registered in Hong Kong and the British Virgin Islands.
- The seven operating subsidiaries include Longduoduo Health Technology, Qingguo, Rongbin, Chengheng, Tianju, Julong, and Yihua, all engaged in health consulting and preventive healthcare services.
- The company primarily earns revenue through commissioned sales of health maintenance services provided by Inner Mongolia Honghai Health Management Co., Ltd., with over 99.6% of gross revenue from commissions under agency agreements expiring in 2029.
- Longduoduo's business focuses on prevention of cardiovascular and cerebrovascular diseases, gastrointestinal disorders, and related health conditions.
- The company has incurred ongoing operating losses and negative operating cash flows, with management expressing substantial doubt about its ability to continue as a going concern.
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $1,404,042, current assets of $1,290,934, current liabilities of $1,205,866, resulting in a current ratio of 1.07 and cash ratio of 1.16.
- Revenue for the quarter ended September 30, 2026, was $17,595 with a net loss of $436,962 and basic and diluted EPS of -$0.015 per share.
- Longduoduo relies on dividends from its principal PRC subsidiary to fund its operations and distributions, but PRC regulations restrict upstream profit distributions and currency conversion.
- The company faces regulatory risks including potential restrictions from PRC authorities on foreign investment, cybersecurity, anti-monopoly enforcement, and listing approvals by the China Securities Regulatory Commission (CSRC).
- Longduoduo's auditor is Bush & Associates CPA LLC, headquartered in Nevada, and is subject to PCAOB inspections, mitigating some risks related to audit transparency under the Holding Foreign Companies Accountable Act (HFCAA).
- No dividends or distributions have been made by any subsidiary to Longduoduo or to shareholders as of the latest report.
- The company’s corporate structure has evolved with deregistration of Longduoduo HK in August 2026 and replacement by other intermediary holding companies.
- The company’s operations and financial condition are materially affected by PRC laws and regulations, including foreign exchange controls and withholding taxes on dividends.
- Recent news coverage does not directly mention Longduoduo but includes broader market and regulatory developments relevant to Chinese companies and the healthcare sector.
Generated 2026-11-17
- S1 | 2026-09-30 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-17 | www.nasdaq.com | President Donald Trump Claims to "Have a Very Powerful Power" in the Veto, but a Midterm Election Surprise Can Shake Things Up for the AI Trade | https://www.nasdaq.com/articles/president-donald-trump-claims-have-very-powerful-power-veto-midterm-election-surprise-can
- N2 | 2026-11-17 | www.nasdaq.com | Jensen Huang's Departure as Nvidia CEO Could Have Enormous Consequences for Where the Crypto Market Heads Next. | https://www.nasdaq.com/articles/jensen-huangs-departure-nvidia-ceo-could-have-enormous-consequences-where-crypto-market
- N3 | 2026-11-17 | www.nasdaq.com | Incyte Wins European Approval For Povofortay In Hidradentis Suppurativa | https://www.nasdaq.com/articles/incyte-wins-european-approval-povofortay-hidradentis-suppurativa
- N4 | 2026-11-17 | www.nasdaq.com | Tencent Music Entertainment Group Q3 Sales Increase | https://www.nasdaq.com/articles/tencent-music-entertainment-group-q3-sales-increase
- N5 | 2026-11-17 | www.nasdaq.com | When Should You Claim Social Security if You Have Loads of Savings? | https://www.nasdaq.com/articles/when-should-you-claim-social-security-if-you-have-loads-savings
- N6 | 2026-11-17 | www.nasdaq.com | Beneficient Reports Second Quarter Fiscal 2027 Results | https://www.nasdaq.com/articles/beneficient-reports-second-quarter-fiscal-2027-results
- N7 | 2026-11-17 | www.nasdaq.com | Delek US Holdings, Inc. Repays and Terminates Term Loan Credit Agreement on November 16, 2026 | https://www.nasdaq.com/articles/delek-us-holdings-inc-repays-and-terminates-term-loan-credit-agreement-november-16-2026
- N8 | 2026-11-17 | www.nasdaq.com | EPR Properties Closes $575.0 Million Convertible Senior Notes Offering | https://www.nasdaq.com/articles/epr-properties-closes-5750-million-convertible-senior-notes-offering
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


